To analyze the effect of methylprednisolone stosstherapy on CD4⁺CD25 ⁺ regulatory T cell(Treg)and apoptosis factor CD95 expressions in the external peripheral blood of myasthenia gravis(MG)patients and explore the influencing factors of different clinical efficacy.

Thirty-one patients with MG, admitted to our hospital from January 2013 to September 2015, were included in this study; and 27 normal subjects were selected as control group. Methylprednisolone stosstherapy was given to the patient group. Expressions of Treg and CD95 in peripheral blood were detected by flow cytometry before and after treatment.

Treg percentage of patients whose clinical absolute scale scores less or equal than 3 points and relative scale scores higher than 0.5 after methylprednisolone stosstherapy(13.39%+2.71%)was significantly higher than that of healthy controls(8.35% + 1.87%, P<0.05); Treg percentage of patients whose clinical absolute scale scores greater than 3 as well as relative scale scores less than 0.5 after methylprednisolone stosstherapy(8.17%+1.31%)was slightly lower than that of healthy controls(P>0.05). CD95 percentage of patients whose clinical absolute scale scores less or equal than 3 points and relative scale scores higher than 0.5 after methylprednisolone stosstherapy(36.47%±5.32%)was not statistically different as compared with that of healthy controls(35.28% ± 5.58%, P>0.05), CD95 percentage of patients whose clinical absolute scale scores greater than 3 as well as relative scale scores less than 0.5 after methylprednisolone stosstherapy(34.97%±5.12%)was not statistically different as compared with that of healthy controls(P>0.05).

Treg ratio increases, CD95 change is not obvious in patients whose clinical curative effect is improved markedly after methylprednisolone stosstherapy.

Myasthenia gravis; CD4 ⁺ CD25⁺ regulatory T cell; CD95; Flow cytometry; Methylprednisolone